Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

GE & Accenture Tie Up To Revive US Healthcare Lost Revenue

Published 05/19/2016, 09:17 PM
Updated 07/09/2023, 06:31 AM

GE Healthcare, a division of General Electric Company (NYSE:GE) , recently introduced a new offering in collaboration with Accenture plc (NYSE:ACN) to help improve medical claims processing and related cash flow for healthcare providers. The collaboration was declared at the GE Healthcare’s annual software summit held in Phoenix, AZ.

The new offering is likely to enable healthcare providers save around 25–50%, on an average, on their cost incurred to re-process denied claims. Alongside, this alliance is a strategic step, which will enable General Healthcare deliver best-in-class service to its customers, by partnering with the best in the industry.

Per the collaboration, GE Healthcare will provide its advanced analytics solution, DenialsIQ, whereas Accenture will bring in its experience and expertise in the field of consulting. The new solution is expected to help healthcare providers, including large health systems, physician groups and hospitals, to ascertain the effects of claims management on financial performance and how proper action can help to redesign workflows and financial operations.

The Healthcare industry has been struggling to manage claims denials for a long time. Per a research by Accenture, for every one in five claims that’s denied, it will cost a typical health system $25 per claim to re-process on average. Now, for a health system that is worth a billion dollar, cutting down on claims denials can lead to a 0.5–1% improvement in operating margin, amounting to $5–10 million annually.

General Electric’s DenialsIQ will assist in the smooth functioning of this collaboration. DenialsIQ is an advanced analytics solution from GE Healthcare that uncovers unseen trends from within claims denials to help provider organizations improve financial performance. This system will show administrators hidden patterns and root cause factors before medical claims denials negatively impact the revenue cycle.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Leveraging General Electric’s DenialsIQ solution, Accenture will offer its services in three types of revenue cycle engagements. The collaboration is likely to improve the revenues of both the companies in the long run.

General Electric carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the industry include CLARCOR Inc. (NYSE:CLC) and Honeywell International Inc. (NYSE:HON) . Both stocks carry a Zacks Rank #2 (Buy).



HONEYWELL INTL (HON): Free Stock Analysis Report

GENL ELECTRIC (GE): Free Stock Analysis Report

CLARCOR INC (CLC): Free Stock Analysis Report

ACCENTURE PLC (ACN): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.